• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • Draft QMS requirements for Medical Device 3PL in China now open for comments

Draft QMS requirements for Medical Device 3PL in China now open for comments

3PL for Medical Devices in China
Wednesday, 15 June 2022 / Published in Medical Device, News, NMPA Registration in China

Draft QMS requirements for Medical Device 3PL in China now open for comments

Third-party logistics (3PL) for medical devices in China have been duly regulated according to the respective province. This meant that a total of 39 regulatory guidelines have been issued by the local Medical Products Administrations (MPAs). In order to solve the underlying problem of inconsistency, the NMPA (National Medical Products Administration) has decided to implement a unified set of quality management system (QMS) requirements at the national level.

On June 10, 2022, the NMPA released the draft requirements for the quality management system of third-party logistics for medical devices in China. The draft serves as an appendix to the Good Supply Practice (GSP) for medical devices, and it is currently open for public comments until June 20, 2022.

The GSP for medical devices (No.58-2014) was announced by the NMPA in 2014 to support the implementation of the “Administrative Measures for the Supervision of Medical Device Business Operation”. The Administrative Measures have been amended recently and came into effect on May 1, 2022. Read our separate blog post for more information.

Background to the draft QMS for medical device 3PL in China

During the period between April and December 2021, the NMPA initiated the process to update the GSP appendix. The NMPA actively carried out public consultations and internal meetings with different groups of provincial MPAs, local regulatory departments, industry associations, 3PL enterprises, etc. A total of 383 comments were collected in December 2021, and a closing conference was held by the NMPA in May 2022.

Highlights

According to the draft, a “3PL provider for medical devices” is defined as an enterprise specialized in the provision of transportation and storage services to medical device registrants, filers, and related operating businesses.

Prior to offering such services, the 3PL company should already possess the required credentials such as a medical device business license, filing certificate for business activities, etc. In addition, the draft lists out the basic capabilities of a medical devices 3PL provider including, but not limited to the following:

  • real-time access to a synchronized electronic data interface that is also accessible to the China regulatory departments and 3PL service users
  • access to the information platform for the unique device identification (UDI) system for the traceability of medical devices during transport or storage
  • a fully implemented and operational quality management system for transportation and storage services

If you would like to learn more about 3PL for medical devices in China or our registration and CRO services for medical devices, IVDs, pharmaceuticals, cosmetics or other products, please contact Cisema.

How to submit your comments on the draft QMS requirements for medical device 3PL in China

The deadline for comments is June 20, 2022. Cisema customers may submit their comments to their respective regulatory affairs project manager otherwise comments may be sent directly to qxjgec@nmpa.gov.cn.

By Jacky Li and Victoria Caldy.

GET IN TOUCH

🌐 Send us your enquiry
📚 Request our whitepapers
📣 Sign up for our newsletter

What you can read next

Administrative Measure on Cosmetics Registration and Filing
Cosmetics enterprises quality and safety responsibilities
Cosmetics enterprises quality and safety responsibilities – Draft regulation issued
Certified Expert

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Submission of safety information for cosmetics ingredients

    Submission of safety information for cosmetics raw materials – Draft guidelines issued

    Submission of safety information for cosmetics ...
  • avoid animal testing in Chinaweb-2023

    How to avoid animal testing in China for cosmetics | Cisema Webinar

    China’s beauty and cosmetic market has be...
  • guidelines for medical devices registration

    Guidelines for medical devices registration in China – New development plans in 2023

    Guidelines for medical devices registration in ...
  • China DMF of API

    China DMF of API, Excipient & Packaging Materials: Market & Regulatory | Cisema Webinar

    “China DMF of API, Excipient & Packag...
  • pre-phase III drug clinical trial meeting guidelines

    Pre-phase III drug clinical trial meeting guidelines released

    Pre-phase III drug clinical trial meeting guide...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP